Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
EpiCept buying Maxim Pharma
September 12, 2005
| A version of this story appeared in
Volume 83, Issue 37
EpiCept Corp. is acquiring Maxim Pharmaceuticals for $136 million in stock. The firm, which is keeping the EpiCept name, will focus on pain management and oncology drugs. EpiCept CEO Jack V. Talley will remain in place, as will the firm's New Jersey headquarters. EpiCept says it will continue to operate Maxim's research facility in San Diego. EpiCept shareholders will retain approximately 72% of the merged company's stock.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter